|
PRPF38B expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.6242562850266E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.02251540567977E-13 |
| Normal-vs-Stage2 |
1.44400047474846E-11 |
| Normal-vs-Stage3 |
6.66133814775094E-16 |
| Normal-vs-Stage4 |
2.85940160438258E-11 |
| Stage1-vs-Stage2 |
1.327710E-02 |
| Stage1-vs-Stage3 |
1.676080E-03 |
| Stage1-vs-Stage4 |
3.519500E-02 |
| Stage2-vs-Stage3 |
8.926000E-01 |
| Stage2-vs-Stage4 |
7.184400E-01 |
| Stage3-vs-Stage4 |
7.856800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
8.78569994533507E-09 |
| Normal-vs-Asian |
6.60320000012149E-07 |
| Caucasian-vs-AfricanAmerican |
5.187200E-01 |
| Caucasian-vs-Asian |
2.391400E-01 |
| AfricanAmerican-vs-Asian |
1.764040E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.7348012743289E-11 |
| Normal-vs-Female |
1.6242562850266E-12 |
| Male-vs-Female |
7.970200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
5.38058486654336E-12 |
| Normal-vs-Age(41-60Yrs) |
1.22124532708767E-15 |
| Normal-vs-Age(61-80Yrs) |
1.70696790036118E-12 |
| Normal-vs-Age(81-100Yrs) |
2.57679999560168E-09 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.981800E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
4.350400E-04 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.875800E-03 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.327700E-02 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.234000E-02 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.851400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.142090E-02 |
| Classical-VS-Follicular |
5.376200E-02 |
| Classical-VS-Other |
3.542600E-01 |
| Classical-VS-Normal |
1.26730004268438E-09 |
| Tall-VS-Follicular |
2.246400E-01 |
| Tall-VS-Other |
2.693800E-02 |
| Tall-VS-Normal |
8.08930700202382E-12 |
| Follicular-VS-Other |
1.790240E-01 |
| Follicular-VS-Normal |
7.68818342322675E-12 |
| Other-VS-Normal |
5.512400E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.22044604925031E-16 |
| Normal-vs-N1 |
1.32159999999271E-06 |
| N0-vs-N1 |
1.072790E-01 |
|
|
